The ultimate test of a Dacron (polyethylene terephthalate or PET) arterial prosthesis depends on its ability to retain sufficient strength and durability to function properly for the life of the patient. Because graft recipients appear to be living longer, primarily because of improved medical and surgical treatment of cardiovascular disease, strength and durability of arterial prostheses have become increasingly important. From the time of implantation, all PET prostheses are continuously subjected to the cyclic stresses of pulsatile blood flow with mechanical fatiguing of yarns, as well as chemical and physical alterations associated with biodegradation. Notwithstanding the overall successful use of currently available prostheses, structural failure continues to occur sporadically and is especially noteworthy because of its potentially serious nature and usual occurrence 5 or more years after implantation, when the diagnosis may be overlooked or delayed. A review of the subject is provided based on the premise that timely recognition and appropriate management require a basic understanding of PET prostheses with respect to various fabric constructions and physical properties, graft healing, postoperative dilation, and known causes of structural failure.

Download full-text PDF

Source

Publication Analysis

Top Keywords

structural failure
12
strength durability
8
pet prostheses
8
failure dacron
4
dacron arterial
4
arterial grafts
4
grafts ultimate
4
ultimate test
4
test dacron
4
dacron polyethylene
4

Similar Publications

Heart failure (HF), a chronic and progressive disease, is increasing in prevalence worldwide and is associated with increased hospitalizations and death. Despite notable improvements in medical therapy for HF, patients are still at risk of future negative outcomes. Current guidelines recommend four classes of medication for treating patients with HF, deemed guideline-directed medical therapy (GDMT).

View Article and Find Full Text PDF

Masquelet technique combined with concentrated growth factors for the reconstruction of rabbit mandibular marginal bone defect.

Clin Oral Investig

January 2025

Fujian Key Laboratory of Oral Diseases & Stomatological Key lab of Fujian College and University, School and Hospital of Stomatology, Fujian Medical University, Fuzhou, Fujian Province, 350002, China.

Objective: Both the Masquelet technique (MT) and concentrated growth factors (CGF) reduce early graft loss and improve bone regeneration. This study aims to explore the efficacy of combining MT with CGF for mandibular defect repair by characterizing the induced membrane and assessing in vivo osteogenesis.

Materials And Methods: Three experimental groups were compared: negative control (NC), MT, and Masquelet combined with CGF (MTC).

View Article and Find Full Text PDF

[Current surgical treatment concepts for traumatic fractures of the thoracic and lumbar spine with osteoporotic bone substance].

Unfallchirurgie (Heidelb)

January 2025

Klinik für Unfallchirurgie, Orthopädie, Hand- & Wiederherstellungschirurgie, München Klinik Harlaching, München, Deutschland.

Osteoporosis-related vertebral fractures are among the most frequent fracture entities in geriatric patients. They are associated with far-reaching individual and socioeconomic consequences. Adequate diagnostics and treatment are therefore essential.

View Article and Find Full Text PDF

Fault ruptures induced by earthquakes pose a significant threat to constructions, particularly underground structures such as pile foundations. Among various foundation types, batter pile foundations are widely used due to their ability to resist inclined forces. To gain new insights into the response of batter pile groups to fault ruptures caused by earthquakes, this study investigates the deformation and failure mechanisms of batter pile groups due to the propagation of normal and reverse fault ruptures using 3D numerical modeling.

View Article and Find Full Text PDF

Background: About half of patients with heart failure with mildly reduced or preserved ejection fraction (HFpEF) have type 2 diabetes. In the STEP-HFpEF DM trial of adults with obesity-related HFpEF and type 2 diabetes, subcutaneous once weekly semaglutide 2·4 mg conferred improvements in heart failure-related symptoms and physical limitations, bodyweight, and other heart failure outcomes. We aimed to determine whether these effects of semaglutide differ according to baseline HbA.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!